Masschallenge accepted

International accelerator launches next program in downtown Houston

Midway's GreenStreet in downtown will be the site of MassChallenge Texas' Houston program. Photo via greenstreetdowntown.com

Houston entrepreneurs will have a new accelerator program to choose from — and this one has an international presence.

MassChallenge Texas, which launched in Austin last year, has expanded to include a Houston program that will operate out of downtown's GreenStreet, which is owned and operated by Houston-based Midway Cos. Applications for the 2019 cohort open in April, and the six week program runs from July through August.

The program looks for applicants that haven't raised more than $500,000 in equity-based funding and have generated less than $1 million in revenue over the past year, a release says. The cohort will support 25 startups with free GreenStreet office space, mentorship, investment opportunities, and more, all the while taking no equity in the companies.

By expanding to Houston, MassChallenge Texas is continuing its commitment to strengthening and growing the innovation ecosystem across the Lone Star State, working to make Texas the best place in the world to innovate.

Almost two years ago, the city released a report in which a task force investigated matters pertaining to innovation in Houston.

"In this report, we realized that Houston has a thriving innovation economy, but its potential is limited by the absence of a flourishing startup community," says Mayor Sylvester Turner in a release. "A key recommendation was to create critical mass in a few key areas with access to 'legacy industry' and institutional players as well as an unparalleled array of amenities."

On par with this dedication to developing innovation in Houston, the Downtown Redevelopment Authority has approved an economic development grant to operate the program. The grant will cover up to $2.5 million of operation costs to be distributed to the organization over five years, the release says.

"MassChallenge is an opportunity that we pursued in earnest," says Bob Eury, president of Central Houston and the Downtown Redevelopment Authority, says in the release. "[The grant is] an investment that we believe will garner long-term results for the GreenStreet development, Downtown and the Houston region."

MassChallenge also has locations in Boston, Israel, Mexico, and Switzerland, as well as vertical programs focused on digital health and fintech. Its Texas program was the second location in the United States and the seventh in the world. Since the April 2018 launch in Austin, MassChallenge Texas and its partners have worked to accelerate 84 companies from 5 continents, 11 countries, and five Texas cities and doled out $500,000 to startups.

"The success of the inaugural MassChallenge Texas accelerator proves that the MassChallenge model works in Texas," says John Harthorne, CEO of MassChallenge, in the release. "Houston has a strong emerging entrepreneurial ecosystem and is home to technology-advanced legacy industries—such as energy, life sciences and aerospace — that can be leveraged to help startups at their earliest stages. We are excited to bring MassChallenge to Houston."

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted